Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases, will present an update on the development of its Universal influenza A vaccine MVA-NP+M1 (VTP-100) at the World Vaccine Congress in Barcelona, Spain.

Sarah Gilbert, Professor of Vaccinology at Oxford University and Board Director at Vaccitech, will give the presentation on 29th October from 4:30pm – 4:45pm (CEST) in Room H2.

The presentation is accessible here and from www.vaccitech.co.uk/pipeline